TARO - Taro Pharmaceutical Industries Ltd.
NYSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Haifa,
Israel
Type: Equity
TARO price evolution
TARO
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $58.95 | $56.48 | $119.98 | |
| Short term investments | ||||
| Net receivables | $219.24 | $230.37 | $227.32 | |
| Inventory | $204.82 | $214.82 | $208.19 | |
| Total current assets | $1303.4 | $1347.4 | $1342.56 | |
| Long term investments | ||||
| Property, plant & equipment | $217.59 | $218.38 | $189.89 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $2162.07 | $2163.18 | $2119.47 | |
| Current liabilities | ||||
| Accounts payable | $44.66 | $51.18 | $43.06 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $361.11 | $374.06 | $361.49 | |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $369.06 | $384.09 | $371.92 | |
| Shareholders' equity | ||||
| Retained earnings | ||||
| Other shareholder equity | $1793.01 | $1779.09 | $1747.56 | |
| Total shareholder equity | ||||
| (in millions $) | 1 May 2024 | 1 May 2023 | 30 Apr 2022 | 30 Mar 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $58.95 | $119.98 | $251.13 | $605.18 |
| Short term investments | $569.61 | $418.48 | ||
| Net receivables | $219.24 | $259.47 | $306.7 | $249.63 |
| Inventory | $204.82 | $226.67 | $210.44 | $180.29 |
| Total current assets | $1303.4 | $1336.43 | $1337.89 | $1470.84 |
| Long term investments | $435.19 | $557.21 | ||
| Property, plant & equipment | $217.59 | $190.14 | $199.69 | $187.59 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $2162.07 | $2135.51 | $2176.36 | $2406.87 |
| Current liabilities | ||||
| Accounts payable | $44.66 | $68.48 | $68.23 | $61.17 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $361.11 | $385.55 | $432.12 | $676.3 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $369.06 | $404.65 | $464.92 | $711.42 |
| Shareholders' equity | ||||
| Retained earnings | $2414.14 | $2388.69 | $2338.62 | |
| Other shareholder equity | $1793.01 | $1730.86 | $1711.44 | -$151.62 |
| Total shareholder equity | $1711.44 | $1703.65 | ||
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $157.15 | $148.2 | ||
| Cost of revenue | ||||
| Gross Profit | $79.9 | $73.6 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $64 | $68.86 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $13.14 | $9.11 | ||
| Interest expense | $15.63 | $12.35 | ||
| Net income | ||||
| Net income | $20.21 | $8.55 | ||
| Income (for common shares) | ||||
| (in millions $) | 1 May 2024 | 1 May 2023 | 30 Apr 2022 | 30 Mar 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $629.18 | $572.95 | $561.35 | $548.97 |
| Cost of revenue | $252.31 | |||
| Gross Profit | $304.98 | $268.32 | $293.13 | $296.66 |
| Operating activities | ||||
| Research & development | $60.15 | |||
| Selling, general & administrative | $91.36 | |||
| Total operating expenses | $283.47 | $250.61 | $168.22 | $403.82 |
| Operating income | $145.15 | |||
| Income from continuing operations | ||||
| EBIT | $145.15 | |||
| Income tax expense | $28.8 | $12.77 | $19.59 | $9.67 |
| Interest expense | $56.2 | $18.04 | $10.17 | -$1.36 |
| Net income | ||||
| Net income | $53.87 | $25.45 | $58.27 | -$386.65 |
| Income (for common shares) | -$386.65 | |||
| (in millions $) | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $84.34 | $141.54 | $59.87 | -$38.7 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | ||||
| Effect of exchange rate | -$0.48 | $0.16 | -$0.64 | $0.6 |
| Change in cash and equivalents | $208.41 | $227.91 | $114.52 | -$30.33 |
| (in millions $) | 1 May 2024 | 1 May 2023 | 30 Apr 2022 | 30 Mar 2021 |
|---|---|---|---|---|
| Net income | -$386.65 | |||
| Operating activities | ||||
| Depreciation | $23.68 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $45.77 | |||
| Investing activities | ||||
| Capital expenditures | -$16.99 | |||
| Investments | $84.89 | |||
| Total cash flows from investing | $84.34 | -$125.56 | -$170.58 | $67.74 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$24.93 | -$24.2 | ||
| Effect of exchange rate | -$0.48 | -$2.83 | $0.17 | $2.51 |
| Change in cash and equivalents | $208.41 | -$96.64 | -$354.04 | $91.82 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |